PLX - Protalix BioTherapeutics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.3981
+0.0001 (+0.03%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.3980
Open0.3981
Bid0.2800 x 800
Ask0.0000 x 1300
Day's Range0.3951 - 0.3981
52 Week Range0.2700 - 0.8300
Volume273,470
Avg. Volume386,724
Market Cap59.068M
Beta (3Y Monthly)3.24
PE Ratio (TTM)N/A
EPS (TTM)-0.3540
Earnings DateMar 10, 2016 - Mar 14, 2016
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.30
Trade prices are not sourced from all markets
  • Moving Average Crossover Alert: Protalix BioTherapeutics
    Zackslast month

    Moving Average Crossover Alert: Protalix BioTherapeutics

    Protalix BioTherapeutics, Inc. (PLX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

  • GlobeNewswirelast month

    Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease

    CARMIEL, Israel, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced the completion of enrollment for the BRIDGE phase III clinical trial of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Additionally, the Company provided an update on the enrollment for the BALANCE and BRIGHT phase III clinical trials which, collectively with the BRIDGE study, comprise the phase III clinical development program for PRX-102 for the treatment of Fabry disease.  The BRIGHT study is approximately 90% enrolled and the BALANCE study is approximately 70% enrolled.

  • Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates

    Protalix (PLX) delivered earnings and revenue surprises of -150.00% and -91.71%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Protalix: 3Q Earnings Snapshot

    On a per-share basis, the Carmiel, Israel-based company said it had a loss of 10 cents. The drug developer posted revenue of $663,000 in the period. The company's shares closed at 49 cents. A year ago, ...

  • GlobeNewswire2 months ago

    Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update

    CARMIEL, Israel, Nov. 07, 2018 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.

  • Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know
    Zacks3 months ago

    Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know

    Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire3 months ago

    Protalix BioTherapeutics to Hold Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018

    CARMIEL, Israel, Oct. 29, 2018 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.

  • Benzinga3 months ago

    The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) Amarin Corporation plc (NASDAQ: AMRN ) BIOLINERX Ltd/S ...

  • Benzinga4 months ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

    Biotech shares saw further momentum last week, following up on the gains of the previous two weeks. Will the momentum continue in the upcoming week? Here are the catalytic events that could drive the sector. ...

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: GTx and Protalix BioTherapeutics

    NEW YORK, NY / ACCESSWIRE / September 24, 2018 / Shares of GTx were deep in the red on Friday on disappointing news that the company’s only drug candidate had filed a mid-stage clinical trial. Shares of Protalix BioTherapeutics on the other hand were soaring on positive preliminary data. GTx, Inc. shares closed down a little over 92% on Friday, making it one of the biggest decliners on the Nasdaq.

  • Protalix (PLX) Reports Q2 Loss, Misses Revenue Estimates
    Zacks5 months ago

    Protalix (PLX) Reports Q2 Loss, Misses Revenue Estimates

    Protalix (PLX) delivered earnings and revenue surprises of -33.33% and -71.34%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Who Owns Protalix BioTherapeutics Inc (NYSEMKT:PLX)?
    Simply Wall St.5 months ago

    Who Owns Protalix BioTherapeutics Inc (NYSEMKT:PLX)?

    In this article, I will take a quick look at Protalix BioTherapeutics Inc’s (NYSEMKT:PLX) recent ownership structure – an unconventional investing subject, but an important one. The impact of aRead More...

  • Associated Press5 months ago

    Protalix: 2Q Earnings Snapshot

    On a per-share basis, the Carmiel, Israel-based company said it had a loss of 8 cents. The drug developer posted revenue of $2 million in the period. The company's shares closed at 50 cents. A year ago, ...

  • ACCESSWIRE5 months ago

    Protalix Biotherapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Protalix Biotherapeutics, Inc. (NYSE: PLX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern ...

  • ACCESSWIRE6 months ago

    Free Technical Reports on Sarepta Therapeutics and Three Additional Biotech Equities

    LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. Losses were broad based as seven out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Protalix BioTherapeutics Inc. (NYSE AMER: PLX), Radius Health Inc. (NASDAQ: RDUS), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), and Sarepta Therapeutics Inc. (NASDAQ: SRPT).

  • Why Protalix Expanded Partnership with Chiesi
    Market Realist6 months ago

    Why Protalix Expanded Partnership with Chiesi

    On July 24, Protalix BioTherapeutics (PLX) expanded its partnership with Chiesi Farmaceutici. The expansion of the agreement allows Chiesi Farmaceutici exclusive US license for the development and commercialization of PRX-102 (pegunigalsidase alfa), which is Protalix’s modified version of the recombinant alpha-galactosidase-A protein. In October 2017, Protalix and Cheisi entered an exclusive partnership for the development and commercialization of PRX-102 outside the US for the treatment of individuals with Fabry disease.